Pyrotinib is a pan ErbB receptor tyrosine kinase inhibitor targeting HER1/2/4, which inhibits HER2 phosphorylation by blocking the homodimers or heterodimers binding of the EGFR family to HER2, thereby preventing the activation of downstream signaling pathways, and thus inhibiting tumor cell growth (16). The gene discussed is EGFR; the disease is neoplasm.